US Stock MarketDetailed Quotes

SNDX Syndax Pharmaceuticals

Watchlist

14.080
+0.860+6.51%

Close Jan 2 16:00 ET

14.420
+0.340+2.41%

Post 19:05 ET

1.20BMarket Cap-3.87P/E (TTM)

Syndax Pharmaceuticals Stock Forum

Trytosaveabit

Dec 9, 2024 06:45

Update

$Syndax Pharmaceuticals (SNDX.US)$ Reuters· 11 mins ago
Syndax Pharmaceuticals: Subgroup Analyses From Ph 2 Protocol-Defined R/R Mnpm1 Aml Efficacy Population Show Responses Across All Major Subgroups

Jaguar8

Nov 17, 2024 13:32

J.P. Morgan analyst has maintained their bullish stance on stock, giving a Buy rating on November 13. Goldman Sachs give it price target $31.

$Syndax Pharmaceuticals (SNDX.US)$

Jaguar8

Nov 16, 2024 16:41

My watchlist Monday. Why? FDA approval- first of its kind for acute adult and pediatric leukemia

$Syndax Pharmaceuticals (SNDX.US)$

Trytosaveabit

Nov 15, 2024 18:07

Repost of FDA approval! Longer PR because to me this seems like a pretty big deal? More so than most approvals! JMO

$Syndax Pharmaceuticals (SNDX.US)$ But im sure/hoping Dr @Jaguar8 will either confirm or dispute! To me seems pretty AWESOME! ((((((. Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation
1 HOUR AGO, 5:29 PM EST
VIA PR NEWSWIRE
– Approva...

Jaguar8

Nov 15, 2024 16:32

NEWS RECAP

$Syndax Pharmaceuticals (SNDX.US)$
Syndax Announces FDA Approval of Revuforj® (revumenib), the First and Only Menin Inhibitor to Treat Adult and Pediatric Patients with Relapsed or Refractory Acute Leukemia with a KMT2A Translocation

Trytosaveabit

Nov 15, 2024 15:00

News

$Syndax Pharmaceuticals (SNDX.US)$ Reuters· just
FDA Approves Revumenib for Relapsed or Refractory Acute Leukemia With a Kmt2a Translocation

Jaguar8

Nov 12, 2024 06:10

NEWS

$Syndax Pharmaceuticals (SNDX.US)$
Syndax Announces Positive Pivotal Topline Results from Relapsed or Refractory mNPM1 AML Cohort in AUGMENT-101 Trial of Revumenib
Syndax Pharmaceuticals (SNDX)announced positive topline results from the AUGMENT-101 trial of revumenib in relapsed/refractory mNPM1 AML patients. The trial met its primary endpoint with a 23% complete remission rate (p-value = 0.0014) and achieved a 47% overall response rate in a heavily pre-treated population. The safety profil...

Trytosaveabit

Nov 12, 2024 06:03

News

$Syndax Pharmaceuticals (SNDX.US)$ Reuters· 2 mins ago
Syndax Pharmaceuticals Inc - Primary Endpoint Met With 23% Cr/CRH Rate in Phase 2 Trial

Trytosaveabit

Nov 4, 2024 15:05

News

$Syndax Pharmaceuticals (SNDX.US)$ $Royalty Pharma (RPRX.US)$ Press Release: Syndax Pharmaceuticals and Royalty Pharma Enter Into $350 Million Royalty Funding Agreement for Niktimvo(TM)
Dow Jones· 1 min ago

Meltyy

Aug 21, 2024 02:00

FDA PDUFA Update…

🚨 This Week’s PDUFAs:
$Regeneron Pharmaceuticals (REGN.US)$ : 🤔
⇨ Linvoseltamab
‣ Multiple myeloma
‣ PDUFA: 8/22/24 (BLA)
🗓️ Last Week’s PDUFAs:
$Gilead Sciences (GILD.US)$ : Approved 8/14 🎉
⇨ Livdelzi (Seladelpar)
‣ Primary biliary cholangitis (PBC)
‣ PDUFA: 8/14/24 (NDA)
$Ascendis Pharma A/S (ASND.US)$ : Approved 8/12 🎉
⇨ YORVIPATH (palopegteriparatide)
‣ Hypoparathyroidism
‣ PDUFA: 8/14/24 (NDA)
$Syndax Pharmaceuticals (SNDX.US)$ & $Incyte (INCY.US)$ : Approved 8/14 🎉
⇨ Nikt...